351 related articles for article (PubMed ID: 17653791)
21. [Estimation of sodium/iodide symporter gene expression (NIS) in thyroid cancer by RT-PCR technique (preliminary study)].
Tosiek M; Pomorski L; Balcerczak E; Mirowski M; Czyz W
Endokrynol Pol; 2005; 56(1):25-9. PubMed ID: 16335670
[TBL] [Abstract][Full Text] [Related]
22. Renal metastases from thyroid papillary carcinoma: study of sodium iodide symporter expression.
Smallridge RC; Castro MR; Morris JC; Young PR; Reynolds JC; Merino MJ; Sarlis NJ
Thyroid; 2001 Aug; 11(8):795-804. PubMed ID: 11525275
[TBL] [Abstract][Full Text] [Related]
23. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
24. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
25. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
26. The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.
Kotlarek M; Kubiak A; Czetwertyńska M; Świerniak M; Gierlikowski W; Kolanowska M; Bakuła-Zalewska E; Jhiang SM; Jażdżewski K; Wójcicka A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495389
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
[TBL] [Abstract][Full Text] [Related]
28. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
[TBL] [Abstract][Full Text] [Related]
29. [Current TNM system of the UICC/AJCC : the prognostic significance for differentiated thyroid carcinoma].
Stratmann M; Sekulla C; Dralle H; Brauckhoff M
Chirurg; 2012 Jul; 83(7):646-51. PubMed ID: 22273853
[TBL] [Abstract][Full Text] [Related]
30. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
31. [Pathological study on the expression of cell adhesion molecules and metastasis suppressor gene in thyroid follicular carcinoma and papillary carcinoma].
Liu Y; Jiang C; Tan Y
Zhonghua Bing Li Xue Za Zhi; 2002 Aug; 31(4):322-6. PubMed ID: 12417089
[TBL] [Abstract][Full Text] [Related]
32. Morphological difference in adult thyroid papillary carcinoma between Japan and Ukraine.
Ito M; Bogdanova T; Zurnadzhy L; Saenko V; Rogounovitch T; Mitsutake N; Kondo H; Maeda S; Nakashima M; Tronko M; Yamashita S
Endocr J; 2014; 61(12):1221-8. PubMed ID: 25242260
[TBL] [Abstract][Full Text] [Related]
33. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
34. Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of Northern Italy, 1998 to 2009.
Ceresini G; Corcione L; Michiara M; Sgargi P; Teresi G; Gilli A; Usberti E; Silini E; Ceda GP
Cancer; 2012 Nov; 118(22):5473-80. PubMed ID: 22517468
[TBL] [Abstract][Full Text] [Related]
35. Expression of the sodium iodide symporter in differentiated thyroid cancer: clinical evidence.
Schmitz G; Füzesi L; Struck J; Siefker U; Hamann A; Sahlmann CO; Hüfner M; Meller J
Nuklearmedizin; 2005; 44(3):86-93. PubMed ID: 15968416
[TBL] [Abstract][Full Text] [Related]
36. Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis.
Jung YH; Hah JH; Sung MW; Kim KH; Cho SY; Jeon YK
Laryngoscope; 2009 Mar; 119(3):541-8. PubMed ID: 19235753
[TBL] [Abstract][Full Text] [Related]
37. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
[TBL] [Abstract][Full Text] [Related]
38. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
39. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
40. Clinical and pathologic features of "sporadic" papillary thyroid carcinoma registered in the years 2005 to 2008 in children and adolescents of Belarus.
Fridman MV; Savva NN; Krasko OV; Zborovskaya AA; Mankovskaya SV; Schmid KW; Demidchik YE
Thyroid; 2012 Oct; 22(10):1016-24. PubMed ID: 22947350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
